PAVM

PAVmed's stock has been impacted by several events in the past six months. A 1-for-30 reverse stock split became effective on January 2, 2026. The stock price has declined by approximately 27.68% over the last six months and 67.31% over the last year. Lucid Diagnostics announced and closed an $18 million underwritten offering of common stock in April 2026. PAVmed held its Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026, and is scheduled to hold its First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026, while Lucid Diagnostics will hold its First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026. PAVmed reported a GAAP net income of $18.6 million for Q1 2025, primarily driven by the mark-to-market valuation of its equity method investment in Lucid Diagnostics, but a non-GAAP loss of $910,000 for Q1 2025. Full year 2025 earnings showed a loss of US$5.63 per share, a decrease from a profit in FY 2024.